now is possible

Pioneer in the development of personalized medicine for diseases of the nervous system: Neurology and Psychiatry.

Using an innovative scientific and technological methodology, we develop new molecules, as well as diagnostic andprognostic biomarkers to optimize personalized medicine.

Bibliography:1. www.healthfirsteurope.org

2. http://www.euro.who.int/en/what-we-do/health-topics/diseases-and-conditions/mental-health.

3. Acute and long-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.Rush AJ, et al. Am J Pharmacogenomics 2006;163:1905–17.

4. The Promise and Reality of Pharmacogenetics in Psychiatry. Zandi et al. Psychiatr Clin N Am 33 (2010) 181–224.

5. www.brainco.es

Biopharma S.L.

BRAINco Biopharma S.L.Edificio 504. Parque Tecnológico de Bizkaia 48160 Derio (Bilbao). Bizkaia. Spain Telf: +34 94 406 45 25 Fax: +34 94 406 45 26

info@brainco.es www.brainco.es

Oct

ober

201

0

According to WHO reports, mental disorders are considered one of the main health problems worldwide in terms ofprevalence, morbidity, mortality, and costs (3 – 4% GDP). (1,2)

Only 37% of patients suffering from Major Depression reach remission within the first treatment. Treatmentnon-adherence in patients suffering from Schizophrenia is up to 74% during the first 18 months. (3,4)

The low treatment adherence rate in patients suffering from mental disorders is the main barrier to achieve remissionof symptoms and/or disease. The main reason of treatment non-adherence is the lack of efficacy and/or severity of adverse reactions. (5)

Treatmentnon-adherence

Falta de adherencia50%Other reasons

50 %Lack of acySevere Adverse

ReactionsExacerbations

Hospital admissionsIncrease in costs

Aristotle

Needs:

Predict treatment response.

Increase treatment efficacy and safety.

Reduce costs.

Brainchip is an open tool in continuous improvement process which allows midterm further applications.

Ultrarapid Metabolizer

Toxicity Treatment selection:Increase E cacyIncrease SafetyReduce Costs

Poor Metabolizer

Lack of E cacy

Brainchip

Normal Metabolizer

“The aim of speculative science is the truth; the aim ofpractical science is action”

How does it help?Increases levels of effectiveness.

Increases levels of security.

Reduces the costs of the disease.

What is it?

Brainchip is a genotyping DNAchip which determines the polymorphisms involved in the metabolism of Antipsychoticand Antidepressant drugs.

How does it work?

Genetic variability plays a main role in drug treatment response, particularly, polymorphisms related to drugmetabolism(5):

Cytochrome P450 (CYP) are the most important Antipsychotic and Antidepressant phase I drug metabolizingenzymes.

Genetic polymorphisms affect the metabolism of drugs leading to:

• Ultrarapid Metabolizers (UM): Enzymatic activity is increased. Drug plasma levels are lower thannormal conditions. Lack of efficacy.

• Poor Metabolizers (PM): Enzymatic activity is decreased. Drug plasma levels are higher than normalconditions. Risk of adverse reactions.

Brainchip predicts Antipsychotics and Antidepressants treatment response, helping MD to prescribe thebest treatment for each patient: PERSONALIZED MEDICINE.

Pharmacogenetics helps to predict individual

response to drug treatment.